Clinical and molecular effects of oral CCR4 antagonist ...

RPT193, an oral CCR4 antagonist, was tested in healthy and atopic dermatitis (AD) subjects. It was well tolerated, with mild/moderate adverse events. AD subjects showed clinical improvement and skin biomarker changes, indicating RPT193's potential in treating inflammatory skin diseases.